+ T lymphocyte count is !200 cells/mm 3 , and it should be considered when that count is у200, although the optimal timing when it is у200 is unclear. Because preliminary data had suggested that a low CD4 + T lymphocyte percentage (%CD4) is associated with disease progression in persons initiating HAART who have a higher absolute CD4, we sought to further characterize the predictive utility of %CD4.
apy; benefits include suppressing viral replication, preserving immune function, prolonging disease-free survival, and decreasing viral transmission. Even with complete virologic suppression, however, eradication of HIV-1 infection cannot be achieved with current therapy [3, 4] . The risks of therapy include development of drug resistance (which limits future treatment options) and drug toxicity, including lipodystrophy, peripheral neuropathy, dyslipidemia, and premature cardiovascular disease [5] [6] [7] .
In persons with HIV-1 infection, absolute CD4 + T lymphocyte count (absolute CD4) concentration in peripheral blood predicts development of opportunistic illnesses and death due to AIDS [8] [9] [10] [11] . Treatment guidelines regarding initiation of HAART have generally relied on absolute CD4. The current treatment guidelines from the US Department of Health and Hu- man Services [11] and the International AIDS Society-USA [12] base their recommendations on a combination of absolute CD4 and HIV-1 RNA level in plasma. HAART is recommended for all symptomatic persons and, regardless of symptoms, for those with absolute CD4 !200 cells/mm 3 . When absolute CD4 is the basis for decision, treatment should be considered when absolute CD4 is 200-350 cells/mm 3 , although there are insufficient data to support more specific recommendations for asymptomatic persons with an absolute CD4 1200 cells/mm 3 [11, 12] . CD4 + T lymphocyte percentage (%CD4) could potentially add prognostic information and assist in the decision about when to start antiretroviral therapy. Studies from the pre-HAART era found that %CD4 was more stable [13] and had greater prognostic significance than did absolute CD4 [13, 14] [16] . In a singlecenter observational cohort study, however, we found that, in persons with an absolute CD4 у350 cells/mm 3 at the time of initiation of HAART, a %CD4 !17 was associated with an increased risk of progression to a new AIDS-defining event (ADE) or death [17] . The relatively small sample size in that study precluded controlling for other factors via multivariable analysis. Thus, we sought to examine, in HIV-infected persons initiating HAART in a large, multicenter cohort, %CD4's independent predictive utility with respect to progression to either a new ADE or death.
SUBJECTS AND METHODS
Study cohort. The study population was the Collaborations in HIV Outcomes Research/US (CHORUS) cohort. Details regarding CHORUS have been published elsewhere [18] [19] [20] . The present study included persons from CHORUS who were у18 years of age and who had initiated HAART between 1 August 1997 and 1 January 2005. HAART was defined as (1) at least 2 nucleoside reverse-transcriptase inhibitors (NRTIs) in combination with at least 1 protease inhibitor (PI) and/or non-NRTI (NNRTI) or (2) at least 3 NRTIs. For inclusion within the study, persons had to have remained on their first HAART regimen for у30 days; have baseline demographic data; absolute CD4, %CD4, and HIV-1 RNA values available either р180 days before or 7 days after the date of initiation of the first HAART regimen; and have a baseline HIV-1 RNA у5000 copies/mL. Data on prior mono-and/or dual-NRTI antiretroviral therapy (ART) and on prior ADEs were collected. The CHORUS cohort study was approved by local Institutional Review Boards, and all patients gave written informed consent for use of clinical data. To maintain patient confidentiality, only aggregated nonidentifiable patient data were used in the analysis.
Definition of study events. A study event was defined as either the first new ADE or death after initiation of the first HAART regimen. ADEs were identified on the basis of 1993 Centers for Disease Control and Prevention (CDC) classification criteria [21] , excluding diagnoses based on an absolute CD4 !200 cells/mm 3 . Persons who did not experience a study event were followed in the cohort either until the end of the study period (1 August 2005) or until they were lost to followup (defined as the date of either withdrawal from CHORUS or, for persons who did not visit the clinic for 19 months), the last clinic visit.
Statistical analysis. To evaluate the association between %CD4 before initiation of HAART and either ADE or death, we fitted a Cox proportional-hazards model adjusting for absolute CD4, baseline log 10 -transformed HIV-1 RNA, sex, race (white or nonwhite), baseline age, prior ART, prior ADE, and probable route of infection (injection-drug use [IDU] or non-IDU). These variables were chosen for inclusion in the model a priori. %CD4 and absolute CD4 were square-root transformed to normalize the data; hazard ratios (HRs) were based on reverse-transformed values. To avoid assuming linearity in the hazard, continuous predictors (%CD4, absolute CD4, viral load, and age) were expanded by fitting restricted cubic splines. For candidate models, each continuous predictor was assigned the same number of knots (0, 3, 4, or 5). The final model used 3 knots (the optimal number of knots, on the basis of the Akaike information criteria; knots were located at the 10th, 50th, and 90th percentiles). An interaction term (including linear and nonlinear terms) between %CD4 and absolute CD4 was also included in the model. On the basis of evidence of a possible violation to the proportional-hazards assumption, the models were stratified on age quintiles and included age as a continuous predictor to account for possible residual confounding. Colinearity between %CD4 and absolute CD4 was examined by computing the variance inflation factor. Unless otherwise stated, the P values (all 2-sided) and confidence intervals (CIs) did not adjust for the model-fitting uncertainty; the HR CI adjusted for model uncertainty was obtained by bootstrapping the entire model-fitting procedure (1000 bootstrap replications) [22] . All analyses were performed by R statistical software (version 2.3.1; available at: http://www.r -project.org) [23] .
RESULTS
Of a total of 1891 persons who met the inclusion criteria (table  1) , 11% were female, and 18% were African American; the median age at initiation of HAART was 38 years (range, 18-82 years). The probable route of HIV infection reported most frequently, by 1369 persons (72%), was men having sex with men, whereas 108 (6%) reported IDU; for 115 (6%), the probable route of HIV infection was unknown, and these persons were more likely to be white ( ). At baseline, median P p .04 (interquartile range [IQR]) absolute CD4 and %CD4 were 240 cells/mm 3 (107-384 cells/mm 3 ) and 16% (9%-24%), respectively. The first HAART regimen contained a PI in 1261 persons (67%), an NNRTI in 400 (21%), both in 30 (2%), and only у3 NRTIs in 200 (11%). Before initiation of HAART, 541 persons (29%) had a history of an ADE, and 1001 (53%) had received ART: mono-NRTI therapy in 122 (6%), dual NRTIs in 289 (15%), and both in 590 (31%). Over a median follow- Figure 1 shows the relationship between baseline absolute CD4 and %CD4 in the cohort, as a scatter plot and stratified according to traditional CDC cutoffs. The overall correlation was 0.84 ( ; Spearman's r), but there was evidence of P ! .0001 discordance: of persons in the 2 highest absolute-CD4 strata (у350 cells/mm 3 ), 25% had a %CD4 that was less than expected (!21%); of persons in the 2 lowest absolute-CD4 strata (!350 cells/mm 3 ), 17% had a %CD4 у21% ( figure 1, inset  table) .
In the Cox proportional-hazards model adjusted for baseline absolute CD4, viral load, age, sex, race, prior ADE, prior ART, and route of infection, %CD4 was a significant predictor of ADEs and death ( ) (table 2) . At a given absolute CD4, P p .002 persons with a lower %CD4 were more likely to either have an ADE or die; for example, for persons with an absolute CD4 of 240 cells/mm 3 (cohort baseline median), the HR for ADE or death for a %CD4 of 9 versus 24 (25th vs. 75th percentiles) was 1.65 (95% CI, 1.17-2.34; 95% bootstrap CI adjusting for model-fitting uncertainty, 1.17-3.13). The interaction between %CD4 and absolute CD4 was also significant ( ), in-P p .003 dicating that the relationship between %CD4 and ADEs or death varied with different levels of absolute CD4. This significant interaction, along with the nonlinear components of the model ( ), precludes describing the relationship be-P p .02 tween %CD4 and disease progression by use of a single HR. Tables 3 and 4 ). P p .09 Predicted 6-year ADE-free survival curves for a person with a given absolute CD4 were generated as a function of %CD4 ( figure 2 ). These curves demonstrate that, for a given absolute CD4, the adjusted 6-year ADE-free survival rate decreased with lower %CD4 values; for example, after adjustment for all other variables at their median values, the predicted 6-year ADE-free survival rate for a person starting HAART with an absolute CD4 of 250 cells/mm 3 and a %CD4 of 13 is approximately equal to that for a person with an absolute CD4 of 200 cells/ mm 3 and a %CD4 of 16 (the cohort median). Persons with an absolute CD4 of 250 cells/mm 3 and a %CD4 below or above 13 are estimated to have, respectively, lower or higher 6-year ADE-free survival rates. Despite the high correlation between %CD4 and absolute CD4, there was no evidence of colinearity (variance inflation factor, 4.5 and 4.6 for %CD4 and absolute CD4, respectively [HR estimates and 95% CI widths were similar in univariate and multivariable models]).
In secondary analyses, %CD4 remained a significant predictor of disease progression ( ; data not shown). These P ! .05 analyses consisted of multivariable models that adjusted for CHORUS site location; accounted for the missing route of infection variable by using multiple imputation techniques, including a third category in the model that defined route of infection as unknown, or removing the variable from the model; included type of initial HAART; and assumed a linear relationship between continuous predictors and the hazard. In multivariable models that included CD8 + T lymphocyte number, CD8 + T lymphocytes were not associated with HIV disease progression (HR, 1.02;
), nor did their inclusion in the P p .41 model affect the independent effect that %CD4 had on disease progression (HR, 1.57; ). %CD4 remained a significant P p .005 predictor of ADE and death when only those persons having an absolute CD4 1200 cells/mm 3 were included in the analysis ( ), and it tended to predict either progression to ADE P p .03 or death when only those persons without a prior ADE were included in the multivariable model (HR, 1.72; ). P p .06
DISCUSSION
In this cohort, we observed that %CD4 at the time of initiation of HAART was associated with risk of HIV disease progression independent of other clinical factors, including absolute CD4. Our model predicted that, for a person with an absolute CD4 of 240 cells/mm 3 and a %CD4 of 9, the hazard of ADE or death is 65% (95% CI, 17%-134%) greater than that for a person with the same absolute CD4 and a %CD4 of 24, independent of prior ART exposure, prior ADE, HIV RNA level, and other factors shown in table 2. Similarly, a person starting HAART who has an absolute CD4 of 350 cells/mm 3 and a %CD4 of 14 has a slightly lower predicted 6-year ADE-free survival than does a similar person with an absolute CD4 of 200 cells/mm 3 and a %CD4 of 28 (figure 2). Thus, there may be persons with absolute CD4 levels 1200 cells/mm 3 who could derive greater benefit from earlier initiation of HAART than do others; %CD4 may identify such persons and clarify the optimal timing of initiation of HAART.
Our results are important because we quantified the relative contribution of %CD4 to risk of disease progression in persons in this cohort who received HAART. Predictors of HIV disease progression in adults after initiation of HAART have been assessed in several cohorts [24] [25] [26] [27] . To our knowledge, only 2 studies in addition to our previous report [17] have included %CD4 as a covariate. Gebo et al. found that %CD4 did not predict development of an opportunistic infection in persons with an absolute CD4 !350 cells/mm 3 , but their follow-up period was for only 90 days, and persons who did not receive HAART were included [15] . Moore et al. reported that %CD4 was no better than absolute CD4 in predicting mortality in all HIV-infected persons who started HAART but that %CD4 !15 was predictive of death in the subset of patients who were AIDS free and initiated HAART at an absolute CD4 of 200-350 cells/ mm 3 [16] . We studied a large population, including substantial numbers of persons with discordant absolute CD4 and %CD4 values. This approach allowed us to adjust for other important variables that influence HIV disease progression and to determine that %CD4 predicts disease progression independent of absolute CD4. We modeled %CD4, absolute CD4, and HIV RNA as continuous variables, rather than grouping them into 2 or more categories, as we and others had done previously. Maintaining such predictors as continuous variables typically improves power, decreases residual confounding, and minimizes bias [28] . That %CD4 and absolute CD4 were independent predictors of ADE or death could imply that the 2 together provide a more precise measurement of actual CD4 + T cell immunity. In the United States, the current standard for measuring absolute CD4 is to use a flow cytometry-based methodology in which total absolute lymphocyte number and %CD4 are calculated and the 2 are multiplied to obtain absolute CD4. The totallymphocyte count includes many important subpopulations, including CD4 + lymphocytes, CD8 + lymphocytes, and NK cells. To assess whether differences in %CD4 and the corresponding differences in HIV disease progression might be due to CD8 + lymphocytes, we included the latter in secondary multivariable models. CD8 + lymphocyte number was not associated with HIV disease progression, nor did its inclusion in the model negate the independent effect of %CD4 on disease progression. Additionally, in a multivariable model that included the CD8 number but not %CD4, the CD8 number was not associated with disease progression (HR, 0.94;
). We elected not to in-P p .76 clude CD8
+ lymphocytes in the primary multivariable model because these data were missing for 545 (29%) of the persons in this cohort. NK cells comprise a very small proportion of total lymphocytes, are not routinely quantified in clinical practice, and were not measured in the present study, and therefore they could not be included in these analyses.
A limitation of cohort studies in which persons are followed from the time of initiation of HAART is that they do not provide direct information about the optimal time to initiate therapy. The ideal study would be a controlled trial in which persons are randomized to initiate HAART at different levels of either absolute CD4 or %CD4. This is neither ethical nor feasible. Another potential study design might include persons in a cohort at the same absolute CD4 or %CD4 who did not initiate HAART. This is challenging, however, because there are many potential time-dependent confounders associated with the decision to initiate treatment and with disease progression.
Our study has other limitations. The generalizability of our results is uncertain. Our population consisted primarily of white men in North America who acquired HIV through sex with men. It is unclear whether the model derived from this population will apply to populations with different demographic and clinical characteristics. Furthermore, we included in our analysis persons who developed an ADE prior to initiation of HAART. These persons, who comprised more than one quarter of our study cohort, would be considered "symptomatic" and, according to treatment guidelines, should receive HAART. When they were removed from the analysis, %CD4 remained associated with disease progression, although with borderline statistical significance ( ), which was likely P p .06 due to the decreased sample size. We included these persons in the primary analysis because our main study objective was to assess disease progression after initiation of HAART, regardless of prior ADE. Other study limitations included our inability to control for adherence to HAART beyond 30 days or other clinical factors that have previously been reported to be associated with either immune recovery or disease progression, such as absolute-CD4 nadir [29] , hemoglobin [30, 31] , or hepatic enzymes [32] . Not all persons included in the present study were antiretroviral-naive at the time of initiation of HAART, although in the multivariable analyses we did control for prior ART exposure. During much of the study period, combination ART that included 3 NRTIs was considered to be HAART. 3-NRTI regimens are now considered to be less effective than efavirenz-based HAART [33] . However, the type of initial HAART was not associated with an increased risk of disease progression in a secondary analysis.
Our observation that %CD4 is a predictor of ADE-free survival, even after adjustment for absolute CD4, may be particularly relevant in light of recent studies suggesting that there are benefits to early initiation of HAART [34] [35] [36] [37] . Absolute CD4 and %CD4 should be considered when decisions are made regarding which patients may benefit most from earlier initiation of therapy.
